Global data shows nearly 10 per cent of severe Covid-19 cases involve a secondary bacterial co-infection - with
The study, published in the journal iScience, revealed that the addition of a "superbug" - methicillin-resistant Staphylococcus aureus (MRSA) - into the mix could make the Covid-19 outcome even more deadly.
While the mystery of how and why the combination of these two pathogens contributes to the severity of the disease remained unsolved, the researchers identified a protein - IsdA - found in all strains of staph A which boosts SARS-CoV-2 replication by 10- to 15-fold.
The findings of this study are significant and could help inform the development of new therapeutic approaches for Covid-19 patients with bacterial co-infections.
Interestingly, the study also showed that SARS-CoV-2 did not affect the bacteria's growth. This was contrary to what the researchers had initially expected.
"We started with an assumption that SARS-CoV-2 and hospitalisation due to Covid-19 possibly caused patients to be more susceptible to bacterial infections which eventually resulted in worse outcomes," said
"Bacterial infections are one of the most significant complications of respiratory viral infections such as Covid-19 and Influenza A. Despite the use of antibiotics, 25 per cent of patients co-infected with SARS-CoV-2 and bacteria, die as a result. This is especially true for patients who are hospitalised, and even more so for those in intensive care units. We were interested in finding why this happens," said Goncheva, who conducted the study while at the
SEE ALSO: